Abstract

Because it improves adherence without reducing effectiveness, the fixed-dose combination (FDC) of isoniazid and rifampin is widely used for the final 4 months of treatment of pulmonary tuberculosis (TB). Some studies have suggested that FDCs might also be safe and effective during the initial 2-month intensive phase …

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.